Semaglutide for Weight Loss: How It Works, Dosing, and What to Expect

Semaglutide Weight Loss: How This GLP-1 Medication Is Changing the Way We Treat Obesity

If you've been following conversations about weight loss over the past few years, you've almost certainly heard the names Wegovy or Ozempic. Both contain the same active ingredient — semaglutide — and both have generated enormous interest from patients, physicians, and researchers alike. For many people in Maryland and across the country, semaglutide weight loss treatment represents a genuinely new option after years of frustrating results with diet and exercise alone. But what exactly is semaglutide, how does it work, and what should you realistically expect? Let's break it down.

What Is Semaglutide and How Does It Work?

Semaglutide belongs to a class of medications called GLP-1 receptor agonists. GLP-1 stands for glucagon-like peptide-1 — a hormone your body naturally produces after you eat. This hormone plays several important roles: it signals your pancreas to release insulin, slows the rate at which your stomach empties, and — crucially for weight management — sends signals to your brain that help you feel full and satisfied.

Semaglutide mimics this natural hormone, but with a longer-lasting effect. When used at the higher doses approved specifically for weight loss (marketed as Wegovy), it works on appetite-regulating centers in the brain to reduce hunger and food cravings. Evidence suggests this is not simply a matter of willpower — the medication is working on a neurological level to change how your body perceives hunger. That's a meaningful distinction for anyone who has ever been told to "just eat less."

It's worth noting that Ozempic contains semaglutide at a lower dose and is FDA-approved specifically for type 2 diabetes management, though some physicians may discuss its use in other contexts. Wegovy, on the other hand, is FDA-approved specifically for chronic weight management in adults with obesity or overweight with at least one weight-related health condition.

The Dosing Schedule: A Gradual, Step-Up Approach

One of the things that distinguishes semaglutide from older weight loss medications is its carefully structured dosing schedule. Rather than starting at a full therapeutic dose, patients follow a step-up protocol — beginning at a low dose and gradually increasing over several months. This approach is designed to help your body adjust and to minimize side effects.

A typical Wegovy dosing schedule looks something like this:

• Months 1–4: Starting doses ranging from 0.25 mg to 1 mg weekly, increasing gradually every four weeks
• Month 5 onward: Maintenance dose of 2.4 mg once weekly, which is the full therapeutic dose for weight management
• Administration: Self-injected once weekly using a pre-filled pen, typically in the abdomen, thigh, or upper arm
• Consistency matters: The medication works best when taken on the same day each week

Your healthcare provider may adjust this schedule based on how you're tolerating the medication. Some patients stay at a lower dose longer to manage side effects, and that's completely normal. Always follow the specific guidance of your prescribing physician rather than a general schedule you've read about online.

What Results Can You Realistically Expect?

Clinical trials for semaglutide at the weight-loss dose have produced results that genuinely surprised researchers. In the landmark STEP 1 trial, participants using semaglutide 2.4 mg alongside lifestyle changes lost an average of approximately 15% of their body weight over 68 weeks — compared to about 2.4% in the placebo group. Some participants lost significantly more.

That said, it's important to set realistic expectations. Semaglutide is a powerful tool, but it works best as part of a broader approach that includes nutritional guidance, physical activity, and behavioral support. Evidence suggests that people who pair the medication with lifestyle changes tend to see better and more sustained results. Weight loss typically begins within the first few weeks, but the most significant changes often occur between months three and six as the dose increases.

It's also important to understand that semaglutide is generally considered a long-term treatment. Studies have shown that stopping the medication often leads to gradual weight regain, which is why ongoing medical supervision and a plan for long-term management are so important. Talk to your doctor about what a sustainable, personalized plan looks like for you.

Side Effects and Who Should Use Caution

Like all medications, semaglutide comes with potential side effects. The most commonly reported ones are gastrointestinal and tend to be most noticeable when the dose increases. These include:

• Nausea (the most common, especially in early weeks)
• Vomiting or diarrhea
• Constipation
• Stomach discomfort or bloating
• Decreased appetite (which, in this context, is also part of how the medication works)

For most people, these side effects are manageable and improve over time. Eating smaller meals, avoiding high-fat or spicy foods, and staying well-hydrated can all help. Serious side effects are less common but do exist — including a potential risk of pancreatitis and, based on animal studies, a possible association with thyroid tumors (though this has not been confirmed in humans). Semaglutide is not recommended for people with a personal or family history of medullary thyroid carcinoma or a condition called MEN2. A thorough conversation with your healthcare provider before starting is essential.

Insurance Coverage for Semaglutide: A Common Concern in Maryland

One of the biggest barriers people face when considering semaglutide is cost. Without insurance coverage, Wegovy can cost over $1,300 per month — a price that puts it out of reach for many. The good news is that coverage is expanding, and many insurance plans — including some Maryland Medicaid plans and employer-sponsored plans — are beginning to cover GLP-1 medications for weight management when specific clinical criteria are met.

Criteria typically include a BMI over a certain threshold, documentation of obesity-related health conditions (such as high blood pressure, type 2 diabetes, or sleep apnea), and participation in a medically supervised program. Navigating insurance requirements can feel overwhelming, but you don't have to do it alone.

At MetroAI, we help Maryland residents and those in nearby states understand their options for physician-supervised weight loss — including whether their insurance may cover GLP-1 medications like semaglutide. If you're curious about your coverage, you can check your insurance eligibility at metroai.app/maryland-weight-loss — it's completely free and requires no commitment. It's a simple first step toward finding out what's actually available to you.

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider about your individual health situation.